These findings are supported by Goldberg and colleagues [35] who investigated 28 patients with NSCLC receiving PD-1/PD-L1 inhibitors and found that a decrease in ctDNA >50% from baseline was associated with a better prognosis. This evidence concerns the gene CD274 and non-small cell lung carcinoma.